Innovations In Oncology- Focus on Multiple Myeloma

Course Description:

Recent advances in understanding the pathophysiology of multiple myeloma (MM) have led to the approval of novel drug classes and treatment options. Advances in treatment offer hope for patients but require careful selection among a range of agents with various mechanisms of action, toxicity profiles, and considerations for individualizing therapy. Additional promising therapies are currently in the pipeline with a variety of new pathways and treatment approaches under investigation. During this session, presenters will provide an overview of novel treatment options and discuss how emerging innovations may impact the management of MM.

Learning Objectives:

At the completion of this knowledge-based activity, participants should be able to

1. Describe the incidence and current treatment landscape for multiple myeloma.
2. Recognize the mechanisms of action for promising emerging treatment options for patients with multiple
3. Explain the potential impact of emerging treatment options on multiple myeloma treatment guidelines and


Houry Leblebjian, PharmD, BCOP

Clinical Pharmacy Practice Manager

Dana Farber Cancer Institute

Belmont, Mass.


Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth


Coconut Creek, FL

Schedule of Educational Activity:

This activity consists of an audio recording, pre-test assessment questions (not required to pass or continue), post-test questions (required to pass with a score of 70% or higher), and a specific activity evaluation.


The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ACPE UAN: 0233-9999-21-058-H01-P  • Activity Type: Knowledge-Based
Contact Hours: 0.5
Release Date: November 11, 2021 •  Expiration Date: December 31, 2022
Activity Fee: Free for Members and Non-Members

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented upon release. Virtual.CPE credit will be processed and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.

Commercial Support:

This educational activity is supported by unrestricted educational grants from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based, and free of any commercial bias.

System Technical Requirements/Viewing Requirements:

System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-9999-21-058-H01-P 0.5 Contact Hours November 11, 2021 - December 31, 2022